a. Valor LM, Charlesworth P, Humphreys L, Anderson CN, Grant SG. Network activity-independent coordinated gene expression program for synapse assembly. Proc Natl Acad Sci USA. 2007 104(11):4658-63.
b. Valor LM, Jancic D, Lujan R, Barco A. Ultrastructural and transcriptional profiling of neuropathological misregulation of CREB function. Cell Death Differ. 2010 17(10):1636-44.
c. Valor LM, Pulopulos MM, JImenez-Minchan M, Olivares R, Lutz B, Barco A. Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation but does not affect cell viability. J Neurosci. 2011 31(5):1652-63.
d. Valor LM, Guiretti D, López-Atalaya JP, Barco A. Genomic landscape of transcriptional and epigenetic dysregulation in early onset polyglutamine disease. J Neurosci.2013, 33(25): 10471-82.
e. Valor LM, Guiretti D. What’s wrong with epigenetics in Huntington’s disease? Neuropharmacology 2013, 80:103-114.
f. Valor LM. Transcription, epigenetics and ameliorative strategies in Huntington’s disease: a genome-wide perspective. Mol Neurobiol. 2015, 51(1): 406-23.
g. Guiretti D, Sempere A, López-Atalaya JP, Ferrer-Montiel A, Barco A, Valor LM. Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington’s disease in the absence of bulk changes. Neurobiol Dis.2016, 89: 190-201.
h. Hervás-Corpión I, Guiretti D, Alcaraz-Iborra M, Olivares R, Campos-Caro A, Barco A, Valor LM. Early alteration of epigenetic-related transcription in Huntington’s disease mouse models. Sci Rep. 2018 8(1):9925.